^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
Duoenda (mitoxantrone liposomal)
i
Other names: PLM60, 2010L04017, HE071
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
CSPC Pharma
Drug class:
Topoisomerase II inhibitor, DNA intercalator
Related drugs:
2d
Mitoxantrone Hydrochloride Liposome and Enlonstobart Combination Treatment in Patients With Relapsed or Refractory Peripheral T Cell Lymphoma (PTCL) (clinicaltrials.gov)
P1/2, N=43, Not yet recruiting, Sun Yet-Sen University Cancer Center
New P1/2 trial
|
Duoenda (mitoxantrone liposomal) • Enshuxing (enlonstobart)
12d
Primary ALK-Negative Anaplastic Large Cell Lymphoma Mimicking Septic Arthritis in a Diabetic Patient: Diagnostic and Therapeutic Challenges. (PubMed, J Vis Exp)
A carefully staged treatment plan was employed, beginning with corticosteroids and etoposide, followed by liposomal mitoxantrone and the CD30-targeted antibody-drug conjugate brentuximab vedotin. The clinical course highlights the necessity of maintaining a high index of suspicion for lymphoma in refractory joint infections and demonstrates that individualized, stepwise therapy can achieve remission even in critically ill patients with aggressive ALCL. These findings provide valuable insights for improving the diagnosis and management of lymphoma cases that mimic infectious diseases.
Journal
|
ALK (Anaplastic lymphoma kinase) • TNFRSF8 (TNF Receptor Superfamily Member 8)
|
ALK negative
|
etoposide IV • Adcetris (brentuximab vedotin) • Duoenda (mitoxantrone liposomal)
2ms
A prospective multicenter randomized controlled clinical study comparing the efficacy and safety of mitoxantrone hydrochloride liposomes with idarubicin in induction therapy for children with newly diagnosed acute myelocytic leukemia (ChiCTR2500111195)
P=N/A, N=220, Not yet recruiting, The First Affiliated Hospital,Sun Yat-sen University; The First Affiliated Hospital,Sun Yat-sen University
New trial
|
Venclexta (venetoclax) • idarubicin hydrochloride • Duoenda (mitoxantrone liposomal)
2ms
Study on the Efficacy and Safety of Mitoxantrone Liposome-Containing Regimens in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia in the Real World (ChiCTR2500111194)
P4, N=60, Recruiting, Tongji Hospital Affiliated to Tongji Medical College Huazhong University of Science and Technology; Tongji Hospital Affiliated to Tongji Medical Colle
New P4 trial • Real-world evidence
|
Venclexta (venetoclax) • azacitidine • Duoenda (mitoxantrone liposomal)
2ms
A Prospective, Multicenter, Randomized Controlled, Phase II Clinical Study of Venetoclax and Azacitidine Combined with Mitoxantrone Hydrochloride Liposome Injection Versus Intensive Chemotherapy in the Treatment of Newly Diagnosed Intermediate- to High-Risk fit AML (ChiCTR2500109764)
P4, N=198, Not yet recruiting, Tangdu Hospital, Fourth Military Medical University; Tangdu Hospital, Fourth Military Medical University
New P4 trial
|
Venclexta (venetoclax) • azacitidine • Duoenda (mitoxantrone liposomal)
2ms
A multicenter, single-arm, phase II clinical study of mitoxantrone hydrochloride liposome injection combined with azacitidine and venetoclax in the treatment of relapsed/refractory acute myeloid leukemia after standard induction therapy (ChiCTR2500109729)
P4, N=38, Not yet recruiting, The First Affiliated Hospital of Army Medical University; The First Affiliated Hospital of Army Medical University
New P4 trial
|
Venclexta (venetoclax) • azacitidine • Duoenda (mitoxantrone liposomal)
2ms
A multicenter, single-arm, phase II clinical study of mitoxantrone hydrochloride liposome injection combined with azacitidine and venetoclax in the treatment of venetoclax-exposed refractory/relapsed acute myeloid leukemia (ChiCTR2500109360)
P4, N=30, Not yet recruiting, The First Affiliated Hospital of Army Medical University; The First Affiliated Hospital of Army Medical University
New P4 trial
|
Venclexta (venetoclax) • azacitidine • Duoenda (mitoxantrone liposomal)
2ms
Phase II Study Evaluating the Combination of Linperlisib, Azacitidine, and Liposomal Mitoxantrone in Treatment-Naïve Nodal TFH Cell Lymphoma (ChiCTR2500107944)
P2, N=30, Not yet recruiting, The First Affiliated Hospital of Soochow University; The First Affiliated Hospital of Soochow University
New P2 trial
|
azacitidine • Zepsun (donafenib) • Itari (linperlisib) • Duoenda (mitoxantrone liposomal)
3ms
Mitoxantrone Hydrochloride Liposome, Standard-dose of Cytarabine and Venetoclax in the Treatment of R/R AML (clinicaltrials.gov)
P2, N=72, Recruiting, First Affiliated Hospital of Zhejiang University | Phase classification: P=N/A --> P2 | N=20 --> 72 | Trial completion date: Dec 2026 --> Dec 2027 | Trial primary completion date: Dec 2025 --> Dec 2026
Phase classification • Enrollment change • Trial completion date • Trial primary completion date
|
Venclexta (venetoclax) • Duoenda (mitoxantrone liposomal)
3ms
Tislelizumab , Cyclophosphamide, Mitoxantrone Liposomes, Chidamide, and Prednisone in the Treatment of New Diagnosed AITL (clinicaltrials.gov)
P2, N=40, Recruiting, The Affiliated Hospital of Xuzhou Medical University
New P2 trial
|
Tevimbra (tislelizumab-jsgr) • cyclophosphamide • prednisone • Epidaza (chidamide) • Duoenda (mitoxantrone liposomal)
4ms
Treatment of Relapsed or Refractory t(8; 21) AML With Targeted AML1-ETO Neoantigen Cytotoxic T Cells (CTL) (clinicaltrials.gov)
P1, N=16, Enrolling by invitation, BGI, China | Recruiting --> Enrolling by invitation
Enrollment status
|
cyclophosphamide • decitabine • Duoenda (mitoxantrone liposomal)
5ms
A Single-Arm, Prospective Clinical Study of Venetoclax Combined with Fludarabine, Liposomal Mitoxantrone, and Dexamethasone (FMD Regimen) for the Treatment of Multiple Myeloma with Secondary Extramedullary Disease (ChiCTR2500107131)
P3, N=20, Recruiting, The First Affiliated Hospital of Zhejiang Chinese Medical University; The First Affiliated Hospital of Zhejiang Chinese Medical University
New P3 trial
|
Venclexta (venetoclax) • fludarabine IV • Duoenda (mitoxantrone liposomal)
Share via
